STOCK TITAN

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) announces that President and CEO Rick Pauls will meet with investors and participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 10:00 am ET. Pauls aims to discuss DiaMedica’s clinical development programs and business strategy. The company is focused on developing treatments for neurological disorders and kidney diseases, particularly through its lead candidate, DM199, which is in Phase 2/3 trials for acute ischemic stroke and a Phase 2 trial for chronic kidney disease.

Positive
  • None.
Negative
  • None.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and Chief Executive Officer, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 10:00 am ET. Mr. Pauls looks forward to meeting investors to discuss DiaMedica’s clinical development programs and business strategy.

If you are interested in arranging a one-on-one meeting or listening to the live event, please contact your BTIG conference representative.

About DiaMedica Therapeutics

DiaMedica Therapeutics is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Our lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, we are advancing DM199 in our REMEDY Phase 2/3 trial in the treatment of AIS and completing enrollment in our REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.

FAQ

What is the date and time of the BTIG Virtual Biotechnology Conference for DiaMedica Therapeutics (DMAC)?

The BTIG Virtual Biotechnology Conference for DiaMedica Therapeutics is on August 9, 2021, at 10:00 am ET.

Who is the CEO of DiaMedica Therapeutics and what will he discuss at the conference?

Rick Pauls, the CEO of DiaMedica Therapeutics, will discuss the company's clinical development programs and business strategy at the conference.

What is DM199 and its significance to DiaMedica Therapeutics?

DM199 is DiaMedica's lead candidate, a synthetic form of the KLK1 protein, aimed at treating acute ischemic stroke and chronic kidney disease.

What clinical trials are currently ongoing for DM199?

DM199 is currently advancing in the REMEDY Phase 2/3 trial for acute ischemic stroke and completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.

How can investors arrange meetings with DiaMedica Therapeutics at the conference?

Investors interested in arranging one-on-one meetings with DiaMedica Therapeutics should contact their BTIG conference representative.

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

DMAC Rankings

DMAC Latest News

DMAC Stock Data

226.63M
26.04M
26.23%
31.61%
0.41%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MINNEAPOLIS